BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:22 PM
 | 
Mar 17, 2009
 |  BC Extra  |  Company News

FDA briefing documents note Xarelto bleeding

FDA briefing documents released in advance of Thursday's Cardiovascular and Renal Drugs Advisory Committee meeting on Xarelto rivaroxaban from Johnson & Johnson (NYSE:JNJ) and Bayer (Xetra:BAY) suggest the discussion will focus on safety issues, especially the potential for Xarelto to cause serious bleeding. The sponsors...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >